Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

Fig. 3

FibroScan® scores before treatment and at the end of the study. FibroScan® scores were divided to three categories: black- F0–1 - absent or mild fibrosis (< 7 kPa); white – F2 - moderate fibrosis (7 < and < 9.5 kPa); grey – F3–4 - severe fibrosis/cirrhosis (> 9.5 kPa). Baseline scores disparity was compared to end of study scores disparity (12 weeks after last treatment) (p = 0.045, Pearson Chi-Square test). Data is presented as number (%)

Back to article page